{"id":4183,"date":"2025-05-28T10:54:32","date_gmt":"2025-05-28T07:54:32","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=4183"},"modified":"2025-05-28T10:54:33","modified_gmt":"2025-05-28T07:54:33","slug":"aifd-uyelerinin-2024-yili-toplam-klinik-arastirma-yatirim-miktari-yuzde-69-artti","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=4183","title":{"rendered":"AIFD \u00dcyelerinin 2024 Y\u0131l\u0131 Toplam Klinik Ara\u015ft\u0131rma Yat\u0131r\u0131m Miktar\u0131 Y\u00fczde 69 Artt\u0131"},"content":{"rendered":"\n

Ara\u015ft\u0131rmac\u0131 \u0130la\u00e7 Firmalar\u0131 Derne\u011fi\u2019nin (AIFD) 2024 Klinik Ara\u015ft\u0131rmalar Yat\u0131r\u0131m Anketi\u2019ne g\u00f6re, T\u00fcrkiye\u2019de klinik ara\u015ft\u0131rma yat\u0131r\u0131mlar\u0131 TL baz\u0131nda y\u00fczde 69 artarak 17 milyar TL\u2019yi a\u015ft\u0131. Dolar baz\u0131nda ise yat\u0131r\u0131mlar 520 milyon dolara yakla\u015ft\u0131. Son be\u015f y\u0131lda y\u0131ll\u0131k ortalama b\u00fcy\u00fcme oran\u0131 y\u00fczde 89,7\u2019ye ula\u015ft\u0131.<\/strong><\/strong><\/p>\n\n\n\n

T\u00fcrkiye\u2019de yenilik\u00e7i ila\u00e7lara ve tedavilere eri\u015fimi h\u0131zland\u0131rmak ve T\u00fcrkiye\u2019nin ila\u00e7 ara\u015ft\u0131rma ve geli\u015ftirme (Ar-Ge) alan\u0131ndaki k\u00fcresel rekabet g\u00fcc\u00fcn\u00fc art\u0131rmak i\u00e7in faaliyet g\u00f6steren Ara\u015ft\u0131rmac\u0131 \u0130la\u00e7 Firmalar\u0131 Derne\u011fi (AIFD), 27 May\u0131s Sal\u0131 g\u00fcn\u00fc d\u00fczenledi\u011fi bas\u0131n toplant\u0131s\u0131nda T\u00fcrkiye\u2019deki klinik ara\u015ft\u0131rma yat\u0131r\u0131mlar\u0131na dair g\u00fcncel veriler sunan Klinik Ara\u015ft\u0131rma Yat\u0131r\u0131m Anketi\u2019nin 2024 y\u0131l\u0131 sonu\u00e7lar\u0131n\u0131 a\u00e7\u0131klad\u0131.<\/p>\n\n\n\n

Toplant\u0131da ayr\u0131ca AIFD Genel Sekreteri Dr. \u00dcmit Dereli, AIFD Sa\u011fl\u0131k Politikalar\u0131 Direkt\u00f6r\u00fc Dr. Ecz. Nihan Burul Bozkurt, Ankara \u015eehir Hastanesi \u00d6\u011fretim \u00dcyesi Prof. Dr. Mehmet Ali Nahit \u015eendur ve T\u00dcSEB T\u00fcrkiye A\u015f\u0131 Enstit\u00fcs\u00fc Ba\u015fkan\u0131 Prof. Dr. Ate\u015f Kara, anket sonu\u00e7lar\u0131n\u0131n yan\u0131 s\u0131ra klinik ara\u015ft\u0131rmalara dair g\u00fcncel yakla\u015f\u0131mlar\u0131 birlikte de\u011ferlendirdiler.<\/p>\n\n\n\n

Klinik ara\u015ft\u0131rma yat\u0131r\u0131mlar\u0131nda y\u00fczde 69 art\u0131\u015f<\/strong><\/p>\n\n\n\n

AIFD \u00fcyeleri aras\u0131nda yap\u0131lan anketin sonu\u00e7lar\u0131na g\u00f6re klinik ara\u015ft\u0131rmalar i\u00e7in yap\u0131lan toplam yat\u0131r\u0131m miktar\u0131 bir \u00f6nceki y\u0131la k\u0131yasla y\u00fczde 69 oran\u0131nda art\u0131\u015f g\u00f6stererek 17 milyar TL\u2019yi a\u015ft\u0131. Klinik ara\u015ft\u0131rma yat\u0131r\u0131mlar\u0131 dolar baz\u0131nda bir \u00f6nceki y\u0131la k\u0131yasla y\u00fczde 22 oran\u0131nda art\u0131\u015fla 520 milyon dolara yakla\u015ft\u0131. Klinik ara\u015ft\u0131rma yat\u0131r\u0131mlar\u0131nda son 5 y\u0131l\u0131n ortalama y\u0131ll\u0131k b\u00fcy\u00fcme oran\u0131 yakla\u015f\u0131k y\u00fczde 89,7 oldu. Halihaz\u0131rda devam eden klinik ara\u015ft\u0131rma say\u0131s\u0131 645 olurken, ara\u015ft\u0131rmalara kat\u0131lan g\u00f6n\u00fcll\u00fc say\u0131s\u0131 ise 3 bin 437\u2019ye y\u00fckseldi.<\/p>\n\n\n\n

Toplant\u0131da a\u00e7\u0131klamalarda bulunan AIFD Genel Sekreteri Dr. \u00dcmit Dereli, <\/strong>\u201c\u0130la\u00e7 Ar-Ge\u2019sinin en b\u00fcy\u00fck k\u0131sm\u0131n\u0131 olu\u015fturan klinik ara\u015ft\u0131rmalara dair g\u00fcncel yakla\u015f\u0131mlar\u0131, bu alan\u0131n uzman konu\u015fmac\u0131lar\u0131 ile birlikte de\u011ferlendirmekten b\u00fcy\u00fck memnuniyet duyuyoruz. Klinik ara\u015ft\u0131rmalar yaln\u0131zca bug\u00fcn\u00fcn hastalar\u0131na umut sunmakla kalmaz; ayn\u0131 zamanda yar\u0131n\u0131n bilimini, ekonomisini ve toplumsal refah\u0131n\u0131 da in\u015fa eder. G\u00fcn\u00fcm\u00fczde \u00fclkeler, \u00e7ok uluslu klinik ara\u015ft\u0131rmalar\u0131n merkezi olabilmek i\u00e7in yo\u011fun bir rekabet i\u00e7inde. 2023 y\u0131l\u0131 itibar\u0131yla ABD bu alanda liderli\u011fini s\u00fcrd\u00fcr\u00fcrken, \u00c7in ve Kanada gibi \u00fclkeler de klinik ara\u015ft\u0131rma yat\u0131r\u0131mlar\u0131n\u0131 art\u0131rarak \u00f6nemli oyuncular aras\u0131nda yer ald\u0131.T\u00fcrkiye ise son y\u0131llarda ila\u00e7 end\u00fcstrisi destekli en fazla aktif klinik ara\u015ft\u0131rmaya sahip \u00fclkeler s\u0131ralamas\u0131nda \u00f6nemli bir ivme yakalad\u0131. T\u00fcrkiye\u2019nin bu alandaki g\u00fc\u00e7l\u00fc potansiyelini ger\u00e7e\u011fe d\u00f6n\u00fc\u015ft\u00fcrmek i\u00e7in daha fazla i\u015f birli\u011fine, daha fazla vizyona ve kararl\u0131l\u0131kla y\u00fcr\u00fct\u00fclecek politikalara ihtiya\u00e7 var. AIFD olarak \u00fcyelerimizle birlikte T\u00fcrkiye\u2019nin klinik ara\u015ft\u0131rmalarda b\u00f6lgesel de\u011fil, k\u00fcresel bir \u00fcs olabilece\u011fine inan\u0131yor ve bu hedefe ula\u015fmak i\u00e7in t\u00fcm payda\u015flarla birlikte \u00e7al\u0131\u015fmay\u0131 s\u00fcrd\u00fcr\u00fcyoruz\u201d dedi<\/p>\n\n\n\n

Anket sonu\u00e7lar\u0131n\u0131 de\u011ferlendiren AIFD Sa\u011fl\u0131k Politikalar\u0131 Direkt\u00f6r\u00fc Dr. Ecz. Nihan Burul Bozkurt<\/strong>, \u015fu ifadeleri kulland\u0131: \u201cKlinik ara\u015ft\u0131rmalar yaln\u0131zca sa\u011fl\u0131k alan\u0131nda de\u011fil; bilimsel kapasitemizi ve ekonomik b\u00fcy\u00fcmemizi do\u011frudan etkileyen stratejik bir aland\u0131r. Son 5 y\u0131l\u0131n e\u011filimine bak\u0131ld\u0131\u011f\u0131nda, T\u00fcrkiye\u2019de klinik ara\u015ft\u0131rmalara y\u00f6nelik yat\u0131r\u0131m hacminin hem TL baz\u0131nda hem de g\u00f6n\u00fcll\u00fc kat\u0131l\u0131mc\u0131 say\u0131s\u0131 a\u00e7\u0131s\u0131ndan istikrarl\u0131 bi\u00e7imde artt\u0131\u011f\u0131 g\u00f6zlemleniyor. 2024 verileri, T\u00fcrkiye\u2019nin bu alanda ciddi bir ivme yakalad\u0131\u011f\u0131n\u0131 ortaya koyuyor. Ancak s\u00fcrd\u00fcr\u00fclebilir bir ba\u015far\u0131 i\u00e7in klinik ara\u015ft\u0131rma ekosistemine \u00f6zel olarak ortaya konulan b\u00fct\u00fcnc\u00fcl bir strateji ve \u00e7ok payda\u015fl\u0131 bir yol haritas\u0131n\u0131n kararl\u0131l\u0131kla takip edilmesi \u015fart. \u00d6nceki y\u0131llarda kamuoyu ile payla\u015ft\u0131\u011f\u0131m\u0131z \u2018T\u00fcrkiye \u0130\u00e7in Klinik Ara\u015ft\u0131rma Stratejisinin Faydalar\u0131\u2019<\/em> raporumuzda, \u00fclkemizin bu alanda s\u00fcrd\u00fcr\u00fclebilir bir geli\u015fim g\u00f6stermesi i\u00e7in 12 temel politika \u00f6nerisi sunmu\u015ftuk. Bu kapsamda, hekimlerin te\u015fvik edilmesinden etik kurullarda standardizasyona, veri altyap\u0131s\u0131n\u0131n g\u00fc\u00e7lendirilmesinden ruhsat \u00f6ncesi faz 3 \u00e7al\u0131\u015fmalar\u0131n Ar-Ge kapsam\u0131na al\u0131nmas\u0131na kadar pek \u00e7ok alanda sistemsel iyile\u015ftirmeler \u00f6neriyoruz. Klinik ara\u015ft\u0131rmalar\u0131n kalk\u0131nma planlar\u0131 ba\u015fta olmak \u00fczere, \u00fcst d\u00fczey politika belgelerinde de yer ald\u0131\u011f\u0131n\u0131 g\u00f6rmekten memnuniyet duyuyoruz. AIFD olarak, hastalar\u0131m\u0131z i\u00e7in bu d\u00f6n\u00fc\u015f\u00fcm\u00fc, y\u00f6nlendirmeye, devam edece\u011fiz.   \u00dclkemizin sa\u011fl\u0131\u011f\u0131na destek verecek her t\u00fcrl\u00fc \u00e7al\u0131\u015fmaya katk\u0131 sunmaya haz\u0131r\u0131z.\u201d<\/p>\n\n\n\n

Kanserin hem d\u00fcnyada hem T\u00fcrkiye\u2019de giderek b\u00fcy\u00fcyen bir halk sa\u011fl\u0131\u011f\u0131 sorunu oldu\u011funu hat\u0131rlatan Ankara \u015eehir Hastanesi \u00d6\u011fretim \u00dcyesi Prof. Dr. Mehmet Ali Nahit \u015eendur<\/strong>, \u015funlar\u0131 s\u00f6yledi: \u201cKanserin hem d\u00fcnyada hem T\u00fcrkiye\u2019de giderek b\u00fcy\u00fcyen bir halk sa\u011fl\u0131\u011f\u0131 sorunu oldu\u011funu hat\u0131rlatan Ankara \u015eehir Hastanesi \u00d6\u011fretim \u00dcyesi Prof. Dr. Mehmet Ali Nahit \u015eendur, \u015funlar\u0131 s\u00f6yledi: \u201c\u00dclkemizde her y\u0131l 240 binden fazla ki\u015fiye kanser tan\u0131s\u0131 konuyor. Son 30 y\u0131lda 10 y\u0131ll\u0131k sa\u011fkal\u0131m oranlar\u0131 y\u00fczde 30\u2019lardan %70\u2019lere \u00e7\u0131kt\u0131; bir\u00e7ok hastal\u0131kta ki\u015fiselle\u015ftirilmi\u015f tedavi se\u00e7enekleriyle hastalar\u0131m\u0131z\u0131n ya\u015fam s\u00fcresi ve kalitesi ciddi bi\u00e7imde artt\u0131. Bu de\u011fi\u015fimi m\u00fcmk\u00fcn k\u0131lan, klinik ara\u015ft\u0131rmalard\u0131r. Bug\u00fcn d\u00fcnyada en \u00e7ok klinik ara\u015ft\u0131rma onkoloji alan\u0131nda y\u00fcr\u00fct\u00fcl\u00fcyor. Son 10 y\u0131lda kanser tedavisinde klinik ara\u015ft\u0131rmalar sayesinde ya\u015fanan de\u011fi\u015fim bir devrim niteli\u011finde. \u00d6rne\u011fin, bug\u00fcn kronik myeloid l\u00f6semi tan\u0131s\u0131 alan hastalar, sa\u011fl\u0131kl\u0131 bireylerle ayn\u0131 ya\u015fam s\u00fcresine sahip. Akci\u011fer kanseri gibi yayg\u0131n ve zorlu alanlarda bile elimizde art\u0131k onlarca onayl\u0131 ila\u00e7 var. \u0130\u015fte bu y\u00fczden klinik ara\u015ft\u0131rmalar \u00e7ok de\u011ferli: Hastalara hen\u00fcz onaylanmam\u0131\u015f ama umut vaat eden tedavilere eri\u015fim sa\u011fl\u0131yor, ‘art\u0131 bir \u015fans’ veriyor. Biz hekimler i\u00e7in de bu sadece bilimsel bir s\u00fcre\u00e7 de\u011fil; bir hastaya kan\u0131tlanm\u0131\u015f yeni bir tedaviyi sunabilmenin mutlulu\u011fu. Klinik ara\u015ft\u0131rmalar bizim i\u00e7in de\u011fil, hastalar i\u00e7in var. Bu alanda T\u00fcrkiye olarak \u00fczerine koyarak ilerliyoruz. Hasta memnuniyeti, bilimsel katk\u0131 ve uluslararas\u0131 i\u015f birlikleriyle her ge\u00e7en g\u00fcn daha da g\u00fc\u00e7leniyoruz.<\/p>\n\n\n\n

Klinik ara\u015ft\u0131rma s\u00fcre\u00e7lerinden g\u00f6n\u00fcll\u00fcl\u00fc\u011fe kadar bir\u00e7ok alanda \u00f6nemli geli\u015fmeleri aktaran,\u00a0Hacettepe \u00dcniversitesi T\u0131p Fak\u00fcltesi \u00d6\u011fretim \u00dcyesi ve T\u00dcSEB T\u00fcrkiye A\u015f\u0131 Enstit\u00fcs\u00fc Ba\u015fkan\u0131 Prof. Dr. Ate\u015f Kara ise \u015funlar\u0131 s\u00f6yledi: \u201cKlinik ara\u015ft\u0131rmalar, bir hayalle ba\u015flar ama bu hayalin tedaviye d\u00f6n\u00fc\u015fmesi binlerce ad\u0131ml\u0131k zorlu ve titiz bir s\u00fcrece ba\u011fl\u0131d\u0131r. Bug\u00fcn bir molek\u00fcl\u00fcn faz 1\u2019den faz 3\u2019e ula\u015fma oran\u0131 yaln\u0131zca binde 14, ruhsat alabilme oran\u0131 ise bin molek\u00fclde 1,5\u2019tir. Bu veriler, klinik ara\u015ft\u0131rmalar\u0131n ne denli se\u00e7ici, bilimsel ve g\u00fcvenlilik odakl\u0131 bir sistem \u00fczerine kurulu oldu\u011funu \u00e7ok net ortaya koyuyor. Bu s\u00fcrecin temelinde g\u00f6n\u00fcll\u00fcl\u00fck var. G\u00f6n\u00fcll\u00fclerimiz sayesinde, milyonlarca insan\u0131n hayat\u0131na dokunan yeni nesil tedaviler m\u00fcmk\u00fcn oluyor. Ancak kamuoyunda \u00e7ok az bilinen kritik bir ger\u00e7ek var: Klinik ara\u015ft\u0131rmalarda g\u00f6n\u00fcll\u00fcn\u00fcn klinik \u00e7al\u0131\u015fmadan kaynakl\u0131 ciddi bir yan etki ya\u015fama olas\u0131l\u0131\u011f\u0131 \u00e7ok \u00e7ok d\u00fc\u015f\u00fck oldu\u011fu ve \u00fclkemizde bug\u00fcne kadar yap\u0131lm\u0131\u015f olan \u00e7al\u0131\u015fmalardaki g\u00fcvenlik de\u011ferlendirmelerini, T\u00dcSEB ve T\u00fcrkiye A\u015f\u0131 Enstit\u00fcs\u00fc olarak ger\u00e7ekle\u015ftirdi\u011fimiz \u00e7al\u0131\u015ftaylarla sigorta sekt\u00f6r\u00fcne aktard\u0131k. T\u0130TCK ve AIFD ile birlikte y\u00fcr\u00fctt\u00fc\u011f\u00fcm\u00fcz klinik ara\u015ft\u0131rma s\u00fcre\u00e7lerine y\u00f6nelik biz dizi \u00e7al\u0131\u015ftay sonucunda, bu bilimsel kan\u0131tlar\u0131n da payla\u015f\u0131m\u0131 klinik ara\u015ft\u0131rmalardaki sigorta primlerinin kayda de\u011fer bi\u00e7imde d\u00fc\u015fmesini sa\u011flad\u0131. Bu kazan\u0131m sadece finansal bir iyile\u015fme de\u011fil; daha fazla hastaya ula\u015fmam\u0131z, ara\u015ft\u0131rma s\u00fcre\u00e7lerini h\u0131zland\u0131rmam\u0131z ve sa\u011fl\u0131kta yerli \u00fcretim kapasitemizi g\u00fc\u00e7lendirmemiz i\u00e7in stratejik bir geli\u015fme. T\u00fcrkiye olarak bu alanda \u00e7ok \u00f6nemli avantajlara sahibiz. G\u00fc\u00e7l\u00fc bir sa\u011fl\u0131k kay\u0131t altyap\u0131m\u0131z, y\u00fcksek hasta \u00e7e\u015fitlili\u011fimiz ve klinik deneyim a\u00e7\u0131s\u0131ndan \u00f6ne \u00e7\u0131kan merkezlerimiz var. Bug\u00fcn D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc verisine g\u00f6re T\u00fcrkiye,\u00a0end\u00fcstri ya da akademi destekli ayr\u0131m\u0131 yapmaks\u0131z\u0131n, t\u00fcm fazlara bakt\u0131\u011f\u0131m\u0131zda toplam aktif klinik ara\u015ft\u0131rma say\u0131s\u0131nda 2024 y\u0131l\u0131nda d\u00fcnyada 10. s\u0131rada yer al\u0131yor. Bu s\u0131ralama, \u00fclkemizin k\u00fcresel ara\u015ft\u0131rma yar\u0131\u015f\u0131nda g\u00fc\u00e7l\u00fc bir oyuncu olmaya aday oldu\u011funu g\u00f6steriyor.\u2019\u2019 <\/p>\n","protected":false},"excerpt":{"rendered":"

Ara\u015ft\u0131rmac\u0131 \u0130la\u00e7 Firmalar\u0131 Derne\u011fi\u2019nin (AIFD) 2024 Klinik Ara\u015ft\u0131rmalar Yat\u0131r\u0131m Anketi\u2019ne g\u00f6re, T\u00fcrkiye\u2019de klinik ara\u015ft\u0131rma yat\u0131r\u0131mlar\u0131 TL baz\u0131nda y\u00fczde 69 artarak 17 milyar TL\u2019yi a\u015ft\u0131. Dolar baz\u0131nda ise yat\u0131r\u0131mlar 520 milyon dolara yakla\u015ft\u0131. Son be\u015f y\u0131lda y\u0131ll\u0131k ortalama b\u00fcy\u00fcme oran\u0131 y\u00fczde 89,7\u2019ye ula\u015ft\u0131.<\/p>\n","protected":false},"author":1,"featured_media":4184,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,42],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4183"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4183"}],"version-history":[{"count":1,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4183\/revisions"}],"predecessor-version":[{"id":4185,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4183\/revisions\/4185"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/4184"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4183"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4183"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}